JP2014534262A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534262A5
JP2014534262A5 JP2014543554A JP2014543554A JP2014534262A5 JP 2014534262 A5 JP2014534262 A5 JP 2014534262A5 JP 2014543554 A JP2014543554 A JP 2014543554A JP 2014543554 A JP2014543554 A JP 2014543554A JP 2014534262 A5 JP2014534262 A5 JP 2014534262A5
Authority
JP
Japan
Prior art keywords
vaccine
hsv
polypeptide
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543554A
Other languages
English (en)
Japanese (ja)
Other versions
JP6199878B2 (ja
JP2014534262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066241 external-priority patent/WO2013078299A1/en
Publication of JP2014534262A publication Critical patent/JP2014534262A/ja
Publication of JP2014534262A5 publication Critical patent/JP2014534262A5/ja
Application granted granted Critical
Publication of JP6199878B2 publication Critical patent/JP6199878B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543554A 2011-11-23 2012-11-21 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法 Expired - Fee Related JP6199878B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563507P 2011-11-23 2011-11-23
US61/563,507 2011-11-23
PCT/US2012/066241 WO2013078299A1 (en) 2011-11-23 2012-11-21 Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (3)

Publication Number Publication Date
JP2014534262A JP2014534262A (ja) 2014-12-18
JP2014534262A5 true JP2014534262A5 (enExample) 2016-01-14
JP6199878B2 JP6199878B2 (ja) 2017-09-20

Family

ID=48470287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543554A Expired - Fee Related JP6199878B2 (ja) 2011-11-23 2012-11-21 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法

Country Status (6)

Country Link
US (1) US9624273B2 (enExample)
EP (1) EP2782597B1 (enExample)
JP (1) JP6199878B2 (enExample)
AU (1) AU2012340712B2 (enExample)
CA (1) CA2885693C (enExample)
WO (1) WO2013078299A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2432504B1 (en) 2009-05-22 2019-05-01 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JP3005292B2 (ja) 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994029456A2 (en) 1993-06-08 1994-12-22 Abbott Laboratories Herpes simplex virus type-2 protease
MXPA94006367A (es) 1993-08-20 2004-09-09 Smithkline Beecham Corp Gene novedoso.
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996032962A1 (en) 1995-04-21 1996-10-24 The University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
JP2001508649A (ja) 1996-11-04 2001-07-03 スミスクライン・ビーチャム・コーポレイション ２型単純ヘルペスウイルス由来の新規コーディング配列
AU7597998A (en) 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
AU750720B2 (en) 1998-03-09 2002-07-25 Smithkline Beecham Biologicals (Sa) Combined vaccine compositions
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
NZ515993A (en) 1999-06-10 2004-04-30 Merial Sas DNA vaccines for pets and sport animals
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
TR200200838T2 (tr) 1999-09-30 2002-06-21 University Of Washington İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
CN1222619C (zh) * 1999-12-17 2005-10-12 惠氏控股公司 增强对单纯疱疹病毒疫苗应答的疫苗及其制药应用
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
AU7312801A (en) 2000-06-29 2002-01-14 Corixa Corp Compositions and methods for the diagnosis and treatment of herpes simplex virusinfection
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US7569218B2 (en) 2000-07-27 2009-08-04 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2002317604A1 (en) 2001-07-31 2003-02-17 Corixa Corporation Immunologically significant herpes simplex virus antigens and methods for using same
WO2003020108A2 (en) 2001-09-04 2003-03-13 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
US8501194B2 (en) 2006-03-10 2013-08-06 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
JP5872755B2 (ja) 2006-07-20 2016-03-01 バイカル インコーポレイテッド 抗ｈｓｖ−２ワクチン接種のための組成物および方法
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
WO2008030560A2 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
WO2008140478A2 (en) 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
CA2674051C (en) 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
AU2008274887B2 (en) 2007-07-06 2013-10-31 The University Of Sydney Epitopes of herpes simplex virus
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
ES2845203T3 (es) * 2008-07-01 2021-07-26 Genocea Biosciences Inc Sistema de análisis de antígenos
EP2379106A4 (en) * 2008-12-17 2012-06-13 Genocea Biosciences Inc ANTIGENS OF CHLAMYDIAS AND USES THEREOF
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2432504B1 (en) * 2009-05-22 2019-05-01 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
EP2544693B1 (en) * 2010-03-09 2017-09-13 Biomedical Research Models, Inc. A novel mucosal vaccination approach for herpes simplex virus type-2
JP2013545448A (ja) * 2010-10-20 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原及びその使用
JP6055776B2 (ja) * 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法

Similar Documents

Publication Publication Date Title
Moorlag et al. Non-specific effects of BCG vaccine on viral infections
US11471527B2 (en) Virus-like particles including HBs-L antigen protein for causing immune response against HBV
Dheerasekara et al. Hantavirus infections—treatment and prevention
CN105906721B (zh) 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
ES2224655T3 (es) Vacuna antiviral recombinante de la encefalitis equina venezolana.
JP2024545152A (ja) 単純ヘルペスウイルスｍＲＮＡワクチン
JP2012527486A5 (enExample)
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
JP2016128513A5 (enExample)
Cong et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
Pourchet et al. CD8+ T-cell immune evasion enables oncolytic virus immunotherapy
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
WO2022090679A1 (en) Coronavirus polypeptide
JP2019537555A5 (enExample)
Qi et al. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model
JP2014534262A5 (enExample)
Mohit et al. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections
Molinelli et al. Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways
Yi et al. Intranasal immunization with curdlan induce Th17 responses and enhance protection against enterovirus 71
JP2013545761A5 (enExample)
Zhang et al. ASFV subunit vaccines: Strategies and prospects for future development
WO2022105880A1 (zh) 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
CN118873646A (zh) 一种抑制a组链球菌感染的重组蛋白疫苗及其应用
CN102000330B (zh) 一种核酸疫苗佐剂及其构建方法